HLS Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst on March 13. Analyst David Martin PhD from Bloom Burton maintained a Buy rating on the stock and has a C$12.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Martin PhD has given his Buy rating due to a combination of factors that, in his view, position HLS Therapeutics for improved performance despite a soft quarter. He acknowledges that fourth-quarter 2025 revenue modestly lagged expectations and showed a slight year-over-year decline, but he notes that core products such as Clozaril and Vascepa were broadly stable in local currency, with foreign exchange movements cushioning reported results.
Looking ahead, he highlights the anticipated contribution from NILEMDO as a key catalyst that could reinvigorate growth and expand the company’s cardiovascular portfolio. In his assessment, the market is overly focused on near-term fluctuations and is underestimating the earnings uplift and diversification potential NILEMDO may deliver, leaving the current share price below his view of intrinsic value and supporting a Buy recommendation.